Evaluate the Neurological Effects of EryDex on Subjects With A-T

Summary

This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).

Timeline

Start

2024-06-24

Primary completion

2025-12-17

Completion

2025-12-17

Drugs

Indications